ACADIA Pharmaceuticals (MEX:ACAD) Shiller PE Ratio: (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
77 GF Score
Price MXN499.00
GF Value MXN452.77
Valuation Fairly Valued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


ACADIA Pharmaceuticals  (MEX:ACAD) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


ACADIA Pharmaceuticals Shiller PE Ratio Related Terms


ACADIA Pharmaceuticals Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Shiller PE Ratio Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

MEX:ACAD vs PBLS, DYN, EWTX: Shiller PE Ratio Comparison

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Shiller PE Ratio falls into.


MEX:ACAD
77GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

ACADIA Pharmaceuticals's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, ACADIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.141/333.9520*333.9520
=3.141

Current CPI (Jun. 2026) = 333.9520.

ACADIA Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 -11.795 241.428 -16.315
201612 -13.401 241.432 -18.536
201703 -13.557 243.801 -18.570
201706 -9.942 244.955 -13.554
201709 -9.618 246.819 -13.013
201712 -10.802 246.524 -14.633
201803 -7.994 249.554 -10.698
201806 -10.021 251.989 -13.280
201809 -9.352 252.439 -12.372
201812 -9.817 251.233 -13.049
201903 -11.445 254.202 -15.036
201906 -7.299 256.143 -9.516
201909 -5.725 256.759 -7.446
201912 -6.412 256.974 -8.333
202003 -13.365 258.115 -17.292
202006 -6.232 257.797 -8.073
202009 -11.929 260.280 -15.305
202012 -8.355 260.474 -10.712
202103 -8.585 264.877 -10.824
202106 -5.375 271.696 -6.607
202109 -1.851 274.310 -2.253
202112 -5.539 278.802 -6.635
202203 -13.938 287.504 -16.190
202206 -4.225 296.311 -4.762
202209 -3.420 296.808 -3.848
202212 -5.069 296.797 -5.704
202303 -4.867 301.836 -5.385
202306 0.171 305.109 0.187
202309 -6.968 307.789 -7.560
202312 4.753 306.746 5.175
202403 1.660 312.332 1.775
202406 3.664 314.175 3.895
202409 3.938 315.301 4.171
202412 17.936 315.605 18.979
202503 2.250 319.799 2.350
202506 3.013 322.561 3.119
202509 7.705 324.800 7.922
202512 28.809 324.054 29.689
202603 0.361 330.213 0.365
202606 3.141 333.952 3.141

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN499.00 is trading 10.2% above its estimated GF Value™ of MXN452.77. GuruFocus considers ACADIA Pharmaceuticals to be Fairly Valued.

Key valuation signals for MEX:ACAD:

  • Shiller PE Ratio:
  • GF Value™: MXN452.77 vs. price of MXN499.00 (10.2% above fair value)
  • GF Score™: 77/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
77GF Score

Get the complete analysis for MEX:ACAD

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN499.00
Price
MXN452.77
GF Value